SFA 006
Alternative Names: SFA-006Latest Information Update: 03 Nov 2022
At a glance
- Originator SFA Therapeutics
- Class Anti-infectives; Antivirals
- Mechanism of Action G-protein coupled receptor 43 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I COVID 2019 infections
- Research Cytokine release syndrome; Post acute COVID 19 syndrome; Sepsis
Most Recent Events
- 04 Oct 2022 Early research in Cytokine release syndrome in USA (unspecified route) (SFA therapeutics pipeline, October 2022)
- 04 Oct 2022 Early research in Post-acute-COVID-19-syndrome in USA (unspecified route) (SFA therapeutics pipeline, October 2022)
- 04 Oct 2022 Early research in Sepsis in USA (unspecified route) (SFA therapeutics pipeline, October 2022)